Placebo News and Research

RSS

UCB to sponsor key sets of VIMPAT C-V data at 66th American Epilepsy Society annual meeting

UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, is sponsoring key sets of VIMPAT® (lacosamide) C-V data at the 66th Annual Meeting of the American Epilepsy Society (AES) in San Diego, Calif., November 30 - December 4.

29 Nov 2012

Dutasteride delays PSA progression

The 5α-reductase inhibitor, dutasteride, delays the clinical progression of prostate cancer in patients with prostate-specific antigen levels that have failed to reduce adequately following radical therapy for localized disease, report researchers.

28 Nov 2012

Combination of mixed amphetamine salts and topiramate shows promise for cocaine dependence

Medication development efforts for cocaine dependence have yet to result in an FDA approved treatment. The powerful rewarding effects of cocaine, the profound disruptive impact of cocaine dependence on one's lifestyle, and the tendency of cocaine to attract people who make poor life choices and then exacerbate impulsive behavior all make cocaine a vexing clinical condition.

28 Nov 2012

Off label atypical antipsychotic use lacks safety and effectiveness in patients over 40

In older adults, antipsychotic drugs are commonly prescribed off-label for a number of disorders outside of their Food and Drug Administration (FDA)-approved indications - schizophrenia and bipolar disorder. The largest number of antipsychotic prescriptions in older adults is for behavioral disturbances associated with dementia, some of which carry FDA warnings on prescription information for these drugs.

28 Nov 2012

Tivantinib holds personalized therapy promise in HCC

Tivantinib is an effective second-line therapy for hepatocellular carcinoma patients whose tumors exhibit high MET receptor tyrosine kinase expression, indicate phase II study results.

26 Nov 2012

Accera commences clinical efficacy trial of AC-1204 for mild-to-moderate Alzheimer's disease

Accera, Inc., a privately-held, commercial-stage, healthcare company focused on the discovery and development of innovative clinical applications to address acute and chronic neurodegenerative diseases, announced today the initiation of a clinical efficacy trial examining the effects of AC-1204 in patients with mild-to-moderate Alzheimer's disease (AD).

26 Nov 2012

‘White-coat’ hypertension concern in very elderly

An analysis of the HYVET data suggests that white-coat hypertension may account for a large number of strokes in the very elderly, and should be treated.

23 Nov 2012

Tumour burden predicts prognosis in mRCC

Tumor burden plays an independent prognostic and predictive role in metastatic renal cell carcinoma, a clinical trial shows.

22 Nov 2012

Bowel cancer and GIST patients could benefit from novel oral drug

Two phase 3 trials, published in The Lancet, have shown that a novel oral drug called regorafenib could offer survival benefits to people with bowel (colorectal) cancer or gastrointestinal stromal tumour (GIST) following failure of existing treatments.

22 Nov 2012

Citicoline not superior to placebo in treating traumatic brain injury

Although approved for use for treating traumatic brain injury (TBI) in nearly 60 countries, use of citicoline in a randomized trial that included more than 1,200 participants with TBI did not result in improvement in functional and cognitive status, according to a study appearing in the November 21 issue of JAMA.

22 Nov 2012

Regorafenib able to control resistant gastrointestinal stromal tumor

A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report investigators at Dana-Farber Cancer Institute who led the worldwide clinical trial.

21 Nov 2012

Personality influences placebo response

Researchers have found that resilient, altruistic, and straightforward individuals are significantly more likely to respond to a sham painkilling or placebo injection than those who are angry and hostile.

21 Nov 2012

Musical tones can reset the brain and effectively reduce insomnia

If you are among the 50 percent of Americans who suffer from insomnia, then you have probably tried everything – from warm milk to melatonin pills or prescription medications to induce sleep – with varying degrees of success and side effects. But what if sleep could be achieved not by a substance, but through 'balancing' brain activity?

21 Nov 2012

Scientists extract recent drug trials to tackle Alzheimer's earlier than ever before

Alzheimer's therapeutic trials have gotten bad press lately, but it is not all gloom and doom. As evident at the 5th Clinical Trials in Alzheimer's Disease (CTAD) conference, held 29-31 October in the Principality of Monaco, scientists keep extracting new data from recent drug trials to gear up for a round of new ones that aim to tackle Alzheimer's earlier than ever before.

21 Nov 2012

Novartis receives FDA approval for Flucelvax to prevent seasonal influenza

The U.S. Food and Drug Administration announced today the approval of Flucelvax, the first seasonal influenza vaccine licensed in the United States produced using cultured animal cells, instead of fertilized chicken eggs. Flucelvax is approved to prevent seasonal influenza in people ages 18 years and older.

21 Nov 2012

Aradigm’s Lipoquin provides full protection in murine models of pneumonic plague

Scientists from the UK Defence Science and Technology Laboratory (Dstl) report, in a preliminary study, that they have demonstrated that a single dose of Aradigm Corporation's liposomal ciprofloxacin formulation Lipoquin administered 24 hours after exposure to a lethal dose of the bacterium Yersinia pestis provided full protection in a murine model of pneumonic plague.

20 Nov 2012

Top-line results from Pfizer's pregabalin CR formulation Phase 3 study on fibromyalgia

Pfizer Inc. announced that top-line results of a double-blind, Phase 3 study evaluating pregabalin controlled-release (CR) formulation in patients with fibromyalgia indicate that pregabalin CR had a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR).

20 Nov 2012

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Janssen-Cilag International NV (Janssen) announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of the oral, once-daily medication ZYTIGA for use in combination with prednisone or prednisolone in the treatment of metastatic castration-resistant prostate cancer (mCRPC), in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.

19 Nov 2012

GSK receives FDA approval for PROMACTA to treat thrombocytopenia

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved PROMACTA for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.

19 Nov 2012

Positive results from Genentech Avastin plus temozolomide Phase III study on glioblastoma

Genentech, a member of the Roche Group, today announced results from the positive Phase III AVAglio study. The study showed Avastin (bevacizumab) in combination with radiation and temozolomide chemotherapy reduced the risk of cancer worsening or death (progression-free survival; PFS) by 36 percent compared to radiation and temozolomide chemotherapy plus placebo>th Annual Meeting of the Society for Neuro-Oncology in Washington, D.C.

19 Nov 2012

Placebo News and Research

UCB to sponsor key sets of VIMPAT C-V data at 66th American Epilepsy Society annual meeting

Dutasteride delays PSA progression

Combination of mixed amphetamine salts and topiramate shows promise for cocaine dependence

Off label atypical antipsychotic use lacks safety and effectiveness in patients over 40

Tivantinib holds personalized therapy promise in HCC

Accera commences clinical efficacy trial of AC-1204 for mild-to-moderate Alzheimer's disease

‘White-coat’ hypertension concern in very elderly

Tumour burden predicts prognosis in mRCC

Bowel cancer and GIST patients could benefit from novel oral drug

Citicoline not superior to placebo in treating traumatic brain injury

Regorafenib able to control resistant gastrointestinal stromal tumor

Personality influences placebo response

Musical tones can reset the brain and effectively reduce insomnia

Scientists extract recent drug trials to tackle Alzheimer's earlier than ever before

Novartis receives FDA approval for Flucelvax to prevent seasonal influenza

Aradigm’s Lipoquin provides full protection in murine models of pneumonic plague

Top-line results from Pfizer's pregabalin CR formulation Phase 3 study on fibromyalgia

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

GSK receives FDA approval for PROMACTA to treat thrombocytopenia

Positive results from Genentech Avastin plus temozolomide Phase III study on glioblastoma

Industry Focus eBook - Cell biology (5th edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News